Saturday 17 October 2026
Export SRRK’s income statement to Excel — free account
Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million. In the quarter to June 2026, EPS grew 14.3%, free cash flow grew 8.88% and total debt rose 294.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
39.85
0.79
−1.94%
Follow SRRK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
6.81 | 8.05 | 6.63 | 5.96 | |
Current Ratio |
7.02 | 8.64 | 6.95 | 6.30 | |
Net Debt/EBITDA |
2.72 | 2.78 | 2.93 | 2.60 | |
Debt/Assets |
37.48% | 36.73% | 24.66% | 24.19% | |
Debt/Equity |
0.77 | 0.71 | 0.41 | 0.41 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.64 | 0.78 | 0.83 | 0.67 | |
Capex/Depreciation |
0.00 | (0.34) | (0.10) | 0.40 | |
Interest Coverage |
(24.10) | (44.32) | (36.25) | (77.62) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.54) | (0.65) | (0.66) | (0.61) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.54) | (0.65) | (0.66) | (0.61) | |
Cash per Share |
3.77 | 3.77 | 3.20 | 3.25 | |
Shareholders Equity per Share |
1.94 | 2.17 | 2.14 | 2.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.94 | 2.17 | 2.14 | 2.15 | |
Free Cash Flow |
(70.31) | (82.17) | (75.53) | (69.01) | |
Working Capital |
434.94 | 455.64 | 329.73 | 328.74 | |
Capital Expenditures |
0.00 | (0.07) | (0.03) | (0.08) | |
Net Current Asset Value |
237.42 | 256.04 | 226.36 | 223.99 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
6.05 | 6.83 | 10.20 | 5.42 | |
Average Assets |
431.79 | 471.40 | 439.60 | 295.43 | |
Average Common Equity |
243.54 | 294.17 | 307.06 | 162.10 |
Columns are period end dates